Article

Kids Who Live Far from Liver Transplant Centers More Likely to Die Waiting for Organ

Author(s):

Georgraphy matters in getting a liver transplant. Boston researchers found that living a long distance from a transplant center increased a child's risk of dying while on an organ waiting list, even though that distance did not mean a longer waiting time.

Georgraphy matters in getting a liver transplant. There is ongoing debate about whether to re-district the boundaries used in setting up organ donor/transplant regions and whether that would make the distribution system more fair.

Reporting at the Liver Meeting (AASLD) in San Francisco, CA, Joel Adler, MD of Massachussetts General Hospital in Boston, MA, looked at whether children on waitlists for donor livers are at a disadvantage if they live far from a transplant center.

Adler and colleagues looked at the Scientific Registry of Transplant Recipients and focused on pediatric liver transplant registrants from 2003 to 2012.

He calculate the distant to each patient's nearest transplant center.

He found that in 6,924 cases, the median distance to a center was 65 miles.

While longer distance to center was not associated with spending more time on a waiting list, it was associated with a higher risking of a child dying while on that list. The hazard ratio was 1.7 for such patients.

The researchers adjusted for demographic factors, rural/urban status, and Pediatric End Stage Liver Disease score, a measure of how sick the child was.

His conclusion was that the increased risk of death is patients who live relatively far away from a center is likely due to "decreased access to specialist and tertiary care associated with a transplant center."

These relationships deserve further consideration," Adler wro

t

e in an abstract presented at the conference.

.

"

Related Videos
Caroline Piatek, MD: High HCRU, Patient Concerns Highlight Great Unmet Need in wAIHA
Steven W. Pipe, MD: Supporting Gene Therapy Implementation for Hemophilia
Corinna L. Schultz, MD: Improving Sickle Cell Trait Documentation in Infancy
Sibgha Zaheer, MD: Determining Washout Period With Fitusiran, Emicizumab Transition for Hemophilia
Pavan K. (Tem) Bendapudi, MD: Large-Scale Analyses Elucidate Genetic Risk of Thrombosis
Seema Rani, MD: Examining Sleep Health in Youth With SCD
Daniel Wang: A More Appropriate Ferritin Threshold is Cost-Effective for Iron Deficiency Screening
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
© 2025 MJH Life Sciences

All rights reserved.